皮下异种移植瘤在头颈部鳞状细胞癌个体化放疗中的价值:稳健基因特征与患者和异种移植瘤的放疗结局相关
研究评估用于头颈部鳞状细胞癌(HNSCC)患者的预后生物标志物和分子肿瘤亚型在细胞系来源的HNSCC异种移植瘤模型中的稳健性,并结合异种移植瘤与患者数据开发新的生物标志物特征。纳入59只携带十种HNSCC细胞系异种移植瘤的小鼠和德国癌症联盟放射肿瘤学组(DKTK-ROG)回顾性多中心患者队列242例,所有患者接受术后放化疗(PORT-C)。间充质亚型肿瘤较其他亚型TCD50更高(异种移植瘤,p<0.001)且LRC更低(患者,p<0.001);开发出对TCD50具预后价值的2基因特征(FN1、SERPINE1)(异种移植瘤,p<0.001),并在独立验证中对患者结局具预后价值(LRC:p=0.007)。
要点
- 间充质亚型肿瘤较其他亚型TCD50更高(异种移植瘤,p<0.001)且LRC更低(患者,p<0.001)。
- 缺氧和放疗抵抗相关基因特征与高TCD50值相关,与既往发表的患者数据相似。
- 2基因特征(FN1、SERPINE1)对TCD50具预后价值(异种移植瘤,p<0.001),独立验证中对LRC具预后价值(p=0.007)。
核心结论
- PORT-C术后患者与原发性临床相关照射后皮下异种移植瘤的遗传预后因素显示相似性。
- 所识别的稳健2基因特征可能有助于指导患者分层,但需前瞻性验证。
- 异种移植瘤仍是转化研究中有价值的资源,用于开发个体化放疗。
研究设计与样本
- 研究纳入携带十种HNSCC细胞系异种移植瘤的小鼠(n=59)以及DKTK-ROG回顾性多中心患者队列(n=242),所有患者接受PORT-C。
- 基因表达分析使用GeneChip Human Transcriptome Arrays;异种移植瘤根据其分子亚型和既往建立的基因分类器进行分层,并比较各组间控制50%肿瘤的剂量(TCD50)。
- 结合异种移植瘤和患者数据的差异基因表达分析,开发出用于定义主要终点局部区域控制(LRC)风险组的基因特征。
主要发现
- 间充质亚型肿瘤较其他亚型TCD50更高(异种移植瘤,p<0.001)且LRC更低(患者,p<0.001)。
- 与既往发表的患者数据相似,缺氧和放疗抵抗相关基因特征与高TCD50值相关。
- 开发出2基因特征(FN1、SERPINE1),对TCD50具预后价值(异种移植瘤,p<0.001),并在独立验证中对患者结局具预后价值(LRC:p=0.007)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 所识别的2基因特征需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the robustness of prognostic biomarkers and molecular tumour subtypes developed for patients with head and neck squamous cell carcinoma (HNSCC) on cell-line derived HNSCC xenograft models, and to develop a novel biomarker signature by combining xenograft and patient datasets. MATERIALS AND METHODS: Mice bearing xenografts (n = 59) of ten HNSCC cell lines and a retrospective, multicentre patient cohort (n = 242) of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG) were included. All patients received postoperative radiochemotherapy (PORT-C). Gene expression analysis was conducted using GeneChip Human Transcriptome Arrays. Xenografts were stratified based on their molecular subtypes and previously established gene classifiers. The dose to control 50 % of tumours (TCD50) was compared between these groups. Using differential gene expression analyses combining xenograft and patient data, a gene signature was developed to define risk groups for the primary endpoint loco-regional control (LRC). RESULTS: Tumours of mesenchymal subtype were characterized by a higher TCD50 (xenografts, p < 0.001) and lower LRC (patients, p < 0.001) compared to the other subtypes. Similar to previously published patient data, hypoxia- and radioresistance-related gene signatures were associated with high TCD50 values. A 2-gene signature (FN1, SERPINE1) was developed that was prognostic for TCD50 (xenografts, p < 0.001) and for patient outcome in independent validation (LRC: p = 0.007). CONCLUSION: Genetic prognosticators of outcome for patients after PORT-C and subcutaneous xenografts after primary clinically relevant irradiation show similarity. The identified robust 2-gene signature may help to guide patient stratification, after prospective validation. Thus, xenografts remain a valuable resource for translational research towards the development of individualized radiotherapy.
引用
- Linge A, Patil S, Grosser M, et al. The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: Robust gene signature correlates with radiotherapy outcome in patients and xenografts. Radiother Oncol. 2023. PMID: 38109944. doi:10.1016/j.radonc.2023.110055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。